1
|
Ghyselinck J, Verstrepen L, Moens F, Van Den Abbeele P, Bruggeman A, Said J, Smith B, Barker LA, Jordan C, Leta V, Chaudhuri KR, Basit AW, Gaisford S. Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease. Int J Pharm X 2021; 3:100087. [PMID: 34977556 PMCID: PMC8683682 DOI: 10.1016/j.ijpx.2021.100087] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 06/02/2021] [Accepted: 06/05/2021] [Indexed: 12/18/2022] Open
Abstract
We report here the potential role of a 4-strain probiotic suspension for use with patients with Parkinson's disease (PD). Stool samples from a group of three patients with diagnosed PD were used to create microbiotas in an in-vitro gut model. The effects of dosing with an oral probiotic suspension (Symprove) on bacterial composition and metabolic activity in the microbiotas was evaluated over 48 h and compared with healthy controls. Additionally, the effect of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and wound healing were evaluated in cell culture models. In general, the relative proportions of the main bacterial phyla in the microbiotas of PD patients differed from those of healthy subjects, with levels of Firmicutes raised and levels of Bacteroidetes reduced. Dosing with probiotic resulted in a change in bacterial composition in the microbiotas over a 48 h period. Several other indicators of gut health changed upon dosing with the probiotic; production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines (IL-6, IL-10) increased and levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased. Tight junction integrity was seen to improve with probiotic dosing and wound healing was seen to occur faster than a control. The data suggest that if development and/or progression of PD is influenced by gut microbiota dysbiosis then supplementation of the diet with a properly formulated probiotic may be a useful adjunct to standard treatment in clinic.
Collapse
Affiliation(s)
| | | | | | | | - Arnout Bruggeman
- Department of Neurology, Ghent University Hospital, Ghent, Belgium
| | - Jawal Said
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Barry Smith
- Symprove Ltd, Sandy Farm, The Sands, Farnham, Surrey GU10 1PX, UK
| | - Lynne Ann Barker
- Centre for Behavioural Science and Applied Psychology, Cognition and Neuroscience Group, Sheffield Hallam University, Collegiate Crescent Campus, Sheffield S10 2BQ, UK
| | - Caroline Jordan
- Centre for Behavioural Science and Applied Psychology, Cognition and Neuroscience Group, Sheffield Hallam University, Collegiate Crescent Campus, Sheffield S10 2BQ, UK
| | - Valentina Leta
- Parkinson's Foundation Centre of Excellence, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK
- Institute of Psychiatry, Psychology & Neuroscience, Department of Basic and Clinical Neurosciences, King's College London, De Crespigny Park, London SE5 8AF, UK
| | - K. Ray Chaudhuri
- Parkinson's Foundation Centre of Excellence, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK
- Institute of Psychiatry, Psychology & Neuroscience, Department of Basic and Clinical Neurosciences, King's College London, De Crespigny Park, London SE5 8AF, UK
| | - Abdul W. Basit
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Simon Gaisford
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| |
Collapse
|
2
|
Cabadaj M, Bashir S, Haskins D, Said J, McCoubrey L, Gaisford S, Beezer A. Kinetic analysis of microcalorimetric data derived from microbial growth: Basic theoretical, practical and industrial considerations. J Microbiol Methods 2021; 187:106276. [PMID: 34214601 DOI: 10.1016/j.mimet.2021.106276] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Revised: 06/25/2021] [Accepted: 06/27/2021] [Indexed: 11/19/2022]
Abstract
We report here a mathematical framework for the quantitative interpretation of exponential bacterial growth measured with isothermal microcalorimetry. The method allows determination of many parameters that define the exponential growth phase. To automate the analysis, we also wrote a coding program, so that the approach could be embedded in a commercial setting. As an exemplar, we apply the method to a commercial probiotic product. The outcome was that we could identify characteristic parameters of growth (including rate constant and doubling time), and hence authenticate product quality, within 15 h. This compares favourably with the current 7-10 days required for conventional microbiological assessment (to allow release of product for bottling and marketing) via plating methods. The method would lend itself to growth analysis of single and mixed bacterial cultures.
Collapse
Affiliation(s)
- Miroslav Cabadaj
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK; Symprove Ltd, Sandy Farm, The Sands, Farnham, Surrey, GU10 1PX, UK
| | - Shazia Bashir
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - David Haskins
- The Coach House, Polsted Lane, Compton, Surrey GU3 1JE, UK
| | - Jawal Said
- Cernotas Ltd, Sandy Farm, The Sands, Farnham, Surrey GU10 1PX, UK
| | - Laura McCoubrey
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Simon Gaisford
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
| | - Anthony Beezer
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| |
Collapse
|
3
|
McCoubrey LE, Elbadawi M, Orlu M, Gaisford S, Basit AW. Harnessing machine learning for development of microbiome therapeutics. Gut Microbes 2021; 13:1-20. [PMID: 33522391 PMCID: PMC7872042 DOI: 10.1080/19490976.2021.1872323] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Accepted: 12/20/2020] [Indexed: 02/06/2023] Open
Abstract
The last twenty years of seminal microbiome research has uncovered microbiota's intrinsic relationship with human health. Studies elucidating the relationship between an unbalanced microbiome and disease are currently published daily. As such, microbiome big data have become a reality that provide a mine of information for the development of new therapeutics. Machine learning (ML), a branch of artificial intelligence, offers powerful techniques for big data analysis and prediction-making, that are out of reach of human intellect alone. This review will explore how ML can be applied for the development of microbiome-targeted therapeutics. A background on ML will be given, followed by a guide on where to find reliable microbiome big data. Existing applications and opportunities will be discussed, including the use of ML to discover, design, and characterize microbiome therapeutics. The use of ML to optimize advanced processes, such as 3D printing and in silico prediction of drug-microbiome interactions, will also be highlighted. Finally, barriers to adoption of ML in academic and industrial settings will be examined, concluded by a future outlook for the field.
Collapse
Affiliation(s)
| | - Moe Elbadawi
- UCL School of Pharmacy, University College London, London, UK
| | - Mine Orlu
- UCL School of Pharmacy, University College London, London, UK
| | - Simon Gaisford
- UCL School of Pharmacy, University College London, London, UK
- FabRx Ltd., Ashford, Kent, UK
| | - Abdul W. Basit
- UCL School of Pharmacy, University College London, London, UK
| |
Collapse
|
4
|
Dodoo CC, Stapleton P, Basit AW, Gaisford S. The potential of Streptococcus salivarius oral films in the management of dental caries: An inkjet printing approach. Int J Pharm 2020; 591:119962. [PMID: 33049357 DOI: 10.1016/j.ijpharm.2020.119962] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 10/05/2020] [Accepted: 10/06/2020] [Indexed: 02/07/2023]
Abstract
The use of probiotics, which can be administered in oro-dispersible films (ODFs) and have prolonged activity in the mouth, was explored. ODFs made of xylitol and containing Streptococcus salivarius were formulated using inkjet printing and tested against Streptococcus mutans - a causative organism of dental caries. The testing of the prepared ODFs involved co-incubating an ink-jetted formulation of S. salivarius and xylitol with S. mutans and monitoring the microbial growth kinetics in real-time using isothermal microcalorimetry and colony plate counts. Cell-free supernatants (CFS) of S. salivarius were also tested against S. mutans. The phosphate solubilisation potential of S. salivarius was also determined and found to be negative, an indication that the species will not deplete phosphate from teeth. From the tests, it was observed that the formulation reduced the S. mutans population from 7.9 to 5.04 Log CFU/mL post-calorimetry (approximately 3 Log reduction) which was comparable to the 99.9% reduction expected during antimicrobial activity testing. A gradual decrease in S. mutans population was also observed with increasing of CFS of S. salivarius volumes indicative of pathogen suppression. This study demonstrates that S. salivarius can be useful in managing dental caries and ODFs of S. salivarius can be formulated easily using ink-jetting for such management.
Collapse
Affiliation(s)
- Cornelius C Dodoo
- School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
| | - Paul Stapleton
- School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Abdul W Basit
- School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Simon Gaisford
- School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
| |
Collapse
|
5
|
Coombes Z, Yadav V, E. McCoubrey L, Freire C, W. Basit A, Conlan RS, Gonzalez D. Progestogens Are Metabolized by the Gut Microbiota: Implications for Colonic Drug Delivery. Pharmaceutics 2020; 12:pharmaceutics12080760. [PMID: 32806503 PMCID: PMC7464400 DOI: 10.3390/pharmaceutics12080760] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 07/31/2020] [Accepted: 08/07/2020] [Indexed: 02/06/2023] Open
Abstract
Following oral administration, the bioavailability of progestogens is very low and highly variable, in part due to metabolism by cytochrome P450 enzymes found in the mucosa of the small intestine. Conversely, the mucosa in the colon contains much lower levels of cytochrome P450 enzymes, thus, colonic delivery of progestogens may be beneficial. Microbiota in the colon are known to metabolize a great number of drugs, therefore, it is important to understand the stability of these hormones in the presence of colonic flora before developing formulations. The aim of this study was to investigate the stability of three progestogens: progesterone, and its two synthetic analogues, medroxyprogesterone acetate (MPA) and levonorgestrel (LNG), in the presence of human colonic microbiota. Progesterone, MPA, and LNG were incubated in mixed fecal inoculum (simulated human colonic fluid) under anerobic conditions. Progesterone was completely degraded after 2 h, whereas levels of MPA and LNG were still detectable after 24 h. The half-lives of progesterone, MPA, and LNG in fecal inoculum were 28, 644, and 240 min, respectively. This study describes the kinetics of colonic microbial metabolism of these hormones for the first time. MPA and LNG show promise for delivery to the colon, potentially improving pharmacokinetics over current oral delivery methods.
Collapse
Affiliation(s)
- Zoe Coombes
- Institute of Life Science 2, Swansea University Medical School, Swansea University, Singleton, Swansea SA28PP, UK;
- Correspondence: (Z.C.); (A.W.B.); (D.G.); Tel.: +44-1792-295384 (Z.C.); +44-1792-602339 (A.W.B.); +44-2077-535865 (D.G.)
| | - Vipul Yadav
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, WC1N 1AX, UK; (V.Y.); (L.E.M.); (C.F.)
| | - Laura E. McCoubrey
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, WC1N 1AX, UK; (V.Y.); (L.E.M.); (C.F.)
| | - Cristina Freire
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, WC1N 1AX, UK; (V.Y.); (L.E.M.); (C.F.)
- Kuecept Limited, Potters Bar, Hertfordshire EN6 1TL, UK
| | - Abdul W. Basit
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, WC1N 1AX, UK; (V.Y.); (L.E.M.); (C.F.)
- Correspondence: (Z.C.); (A.W.B.); (D.G.); Tel.: +44-1792-295384 (Z.C.); +44-1792-602339 (A.W.B.); +44-2077-535865 (D.G.)
| | - R. Steven Conlan
- Institute of Life Science 2, Swansea University Medical School, Swansea University, Singleton, Swansea SA28PP, UK;
| | - Deyarina Gonzalez
- Institute of Life Science 2, Swansea University Medical School, Swansea University, Singleton, Swansea SA28PP, UK;
- Correspondence: (Z.C.); (A.W.B.); (D.G.); Tel.: +44-1792-295384 (Z.C.); +44-1792-602339 (A.W.B.); +44-2077-535865 (D.G.)
| |
Collapse
|
6
|
A 4-strain probiotic supplement influences gut microbiota composition and gut wall function in patients with ulcerative colitis. Int J Pharm 2020; 587:119648. [PMID: 32679260 DOI: 10.1016/j.ijpharm.2020.119648] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 07/08/2020] [Accepted: 07/09/2020] [Indexed: 12/12/2022]
Abstract
Symprove, a multi-strain probiotic, has been shown to exert a mild anti-inflammatory effect in patients with ulcerative colitis (UC). We examined stool samples from 3 patients with UC in order to create microbiotas in an in-vitro gut model. The effects of Symprove on bacterial diversity and metabolic activity in the microbiotas was evaluated over 48 h. In addition, the influence of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and wound healing were evaluated in cell culture models. The relative proportions of the main bacterial phyla in UC patients differed from those of healthy subjects studied previously; levels of Firmicutes were lowered and levels of Bacteroidetes were raised. Addition of Symprove changed the bacterial composition in the microbiotas over a 48 h period. Several other factors generally implicated in good gut health changed after dosing with probiotic; production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines (IL-6, IL-10) increased, levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased, epithelial tight junction integrity improved and wound healing occurred faster than a control. The results imply it is not the simple addition of probiotic bacteria that improves gut health. Rather, the probiotic bacteria generate lactate, which then stimulates growth of commensal gut bacteria, raising SCFA levels (particularly butyrate). The increased butyrate concentration positively influences inflammation response and time of wound healing.
Collapse
|
7
|
Abstract
Abstract
Purpose of Review
We examine recent developments in the treatment of cirrhosis by gut microbiome manipulation specifically focusing on the phase 1 safety and feasibility trials of faecal microbiota transplantation (FMT). We interrogate the published data so far on its feasibility, safety and efficacy.
Recent Findings
A large number of trials have demonstrated the efficacy of FMT in treating recurrent Clostridium difficile infection which is now considered standard of care. In cirrhosis, FMT is still being evaluated and there are a number of clinical trials underway. There are two phase 1 pilot safety studies that have been published with promising findings. However, the importance of rigorously testing donor stool for the presence of multi-drug resistant species has been highlighted and lessons have been learned.
Summary
For those patients with cirrhosis, replacing an unhealthy gut microbiome with a healthy one offers a promising antibiotic-free treatment that may reduce bacterial translocation and endotoxemia.
Collapse
|